United Therapeutics Corp
UTHR
$547.69
-0.32%
United Therapeutics Corp is a biotechnology company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other rare diseases, primarily through its portfolio centered on the prostacyclin pathway and the treprostinil molecule. The company is a leader in the PAH treatment market, distinguished by its multi-product strategy around a single active ingredient and its deep expertise in a specialized therapeutic area. The current investor narrative is heavily driven by positive late-stage clinical data for its lead drug Tyvaso in a new lung disease indication, which promises significant market expansion and was the catalyst for a recent major stock price surge.…
UTHR
United Therapeutics Corp
$547.69
Related headlines
UTHR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on United Therapeutics Corp's 12-month outlook, with a consensus price target around $712.00 and implied upside of +30.0% versus the current price.
Average Target
$712.00
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$438 - $712
Analyst target range
Analyst coverage is limited, with only 5 analysts providing estimates, which is typical for a mid-cap biotech. The consensus sentiment appears bullish, as evidenced by recent institutional ratings which include four 'Buy' or 'Overweight' ratings and one 'Equal Weight' from Wells Fargo, with no sell ratings. However, specific consensus price targets and the implied upside/downside are not available in the provided data, preventing a calculation of the market's explicit price expectation. The lack of a published target price range from the analyst data indicates higher uncertainty or a focus on qualitative assessments over quantitative targets; the wide disparity between the 52-week low and high ($272.12 to $609.35) itself reflects the stock's binary event-driven nature, where the high target would assume successful commercialization of new indications like the recent Tyvaso expansion, while the low likely prices in pipeline failures or competitive threats.
Bulls vs Bears: UTHR Investment Factors
The evidence currently favors the bull case, primarily due to the transformative clinical catalyst for Tyvaso, exceptional underlying profitability, and a valuation that does not appear excessively stretched relative to history. The bear case is grounded in the reality of a mature, low-growth core business and a technically overbought stock price. The single most important tension in the investment debate is the market's valuation of future growth from the new Tyvaso indication against the current financial reality of single-digit revenue growth. The thesis hinges on whether the commercial launch of the new indication can meaningfully accelerate top-line growth to justify and sustain the current valuation multiples.
Bullish
- Exceptional Profitability & Cash Flow: The company's net margin was 46.1% in Q4 2025, and its trailing gross margin is 87.9%, demonstrating immense pricing power in its niche. This profitability fuels a fortress balance sheet with zero debt and generated $1.04 billion in TTM free cash flow, providing significant financial flexibility.
- Major Pipeline Catalyst with Tyvaso: Positive Phase 3 data for Tyvaso in a new lung disease indication, announced in late March 2026, drove a major stock surge and represents a significant potential market expansion. This is the primary driver of the stock's 73.8% one-year gain and shifts the narrative from a mature PAH player to a growth story.
- Strong Technical Momentum & Low Beta: The stock is up 73.81% over the past year and trades at 91% of its 52-week high, indicating powerful bullish momentum. Its beta of 0.595 suggests this move is driven by company-specific catalysts rather than broad market swings, implying lower systemic risk.
- Reasonable Valuation Post-Surge: Despite the large price increase, the trailing P/E of 16.2x is in the middle of its historical range (from 8.7x to 65x) and is reasonable for a highly profitable biotech. The forward P/E of 17.5x implies only modest earnings growth expectations, not an extreme premium.
Bearish
- Mature, Single-Digit Core Growth: Q4 2025 revenue grew only 7.4% YoY, and quarterly revenues have been stable between $735.9M and $799.5M for two years. This indicates the core PAH business is a low-growth cash cow, making the stock dependent on pipeline success for re-acceleration.
- Technically Overextended Near Resistance: Trading at $556.82, the stock is just 8.6% below its 52-week high of $609.35, following a massive rally. The recent 2.5% one-month pullback and high short ratio of 5.37 suggest vulnerability to profit-taking and increased selling pressure at these elevated levels.
- High Reliance on Single Product Family: The company's revenue is heavily concentrated on therapies based on the treprostinil molecule, with Tyvaso DPI noted as the maximum revenue contributor. This creates significant product concentration risk if faced with new competition, generic threats, or clinical setbacks for pipeline expansions.
- Valuation Premium on Slower Growth: The forward P/E of 17.5x is higher than the trailing P/E of 16.2x, implying the market is paying for future growth that has yet to materialize in financials. The PEG ratio of 1.16 also suggests the stock is fairly-to-slightly-overvalued relative to its earnings growth rate.
UTHR Technical Analysis
The stock is in a sustained, powerful uptrend, having gained 73.81% over the past year. As of the latest close at $556.82, the price is trading near the top of its 52-week range (between $272.12 and $609.35), approximately 91% of the way towards its high, indicating strong momentum but also potential overextension and vulnerability to a pullback from resistance. Recent momentum shows volatility within this uptrend; the stock is up 10.50% over the last three months but has pulled back 2.50% over the past month, suggesting a short-term consolidation or profit-taking phase after the significant gains earlier in the quarter, particularly following the late-March surge. Key technical levels are clear, with immediate resistance at the 52-week high of $609.35 and support at the 52-week low of $272.12, though more relevant near-term support lies around the $500 level where the stock consolidated in Q1. The stock's beta of 0.595 indicates it has been significantly less volatile than the broader market, which is unusual for a biotech and suggests its recent large moves are driven by company-specific catalysts rather than sector-wide sentiment.
Beta
0.59
0.59x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$272-$609
Price range past year
Annual Return
+69.1%
Cumulative gain past year
| Period | UTHR Return | S&P 500 |
|---|---|---|
| 1m | -4.3% | +4.6% |
| 3m | +14.5% | +12.6% |
| 6m | +11.9% | +10.4% |
| 1y | +69.1% | +27.0% |
| ytd | +10.3% | +11.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UTHR Fundamental Analysis
Revenue growth is steady but modest; Q4 2025 revenue was $790.2 million, representing a 7.4% year-over-year increase, and quarterly revenues have hovered consistently between $735.9M and $799.5M over the last two years, indicating a stable, mature revenue base with single-digit growth. The company is highly profitable with robust margins; Q4 2025 net income was $364.3 million, translating to a net margin of 46.1%, and the trailing twelve-month gross margin stands at an exceptional 87.9%, demonstrating strong pricing power and cost control within its niche PAH franchise. The balance sheet is exceptionally strong with zero debt (debt-to-equity of 0) and a fortress-like current ratio of 6.6, while the company generated substantial free cash flow of $1.04 billion over the trailing twelve months, providing ample financial flexibility for R&D, business development, and shareholder returns without reliance on external financing.
Quarterly Revenue
$790200000.0B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$1.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UTHR Overvalued?
Given the company's substantial and consistent profitability, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E is 16.2x, while the forward P/E is slightly higher at 17.5x, a modest premium that suggests the market expects stable, not dramatically accelerating, earnings growth. Compared to typical biotechnology industry averages, which often feature higher P/E multiples for growth stories, UTHR's P/E in the mid-teens appears relatively reasonable, especially given its profitability and zero debt, though a direct industry average P/E is not provided in the data for precise comparison. Historically, the stock's own P/E ratio has fluctuated significantly, ranging from a low near 8.7x in early 2024 to a high above 65x in early 2021; the current trailing P/E of 16.2x sits comfortably in the middle of this multi-year range, suggesting the stock is not at extreme historical valuation levels despite its strong price performance.
PE
16.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~66x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: United Therapeutics faces limited financial risk due to its pristine balance sheet with zero debt and a current ratio of 6.6. The primary operational risk is revenue concentration, as the company derives maximum revenue from Tyvaso DPI and its entire portfolio is centered on the treprostinil molecule for PAH. While profitability is robust with a 46.1% net margin, the core business exhibits mature, single-digit growth (7.4% YoY in Q4), creating dependence on pipeline success to drive future earnings expansion and justify its forward P/E of 17.5x.
Market & Competitive Risks: The stock trades at a premium forward earnings multiple despite modest growth, creating valuation compression risk if the Tyvaso launch disappoints or growth fails to re-accelerate. As a biotechnology stock, it faces inherent competitive and regulatory risks in its niche PAH market. Although its beta of 0.595 indicates low correlation to the broader market, the stock has demonstrated high company-specific volatility, as seen in the 16.35% max drawdown, driven by binary clinical news like the recent Tyvaso data release.
Worst-Case Scenario: The most damaging scenario would involve a failed commercial launch for the new Tyvaso indication, combined with increased competitive pressure or generic erosion in its core PAH franchise, leading to declining revenues and compressed margins. This could trigger multiple downgrades from the currently bullish analyst cohort. A realistic downside could see the stock re-testing its 52-week low of $272.12, which would represent a loss of approximately -51% from the current price of $556.82. A more probable adverse scenario, factoring in the strong balance sheet, might see a pullback to the $400-$450 support zone, representing a -20% to -28% decline.